Robert Langer Acquires 93,944 Shares of PureTech Health (LON:PRTC) Stock

PureTech Health plc (LON:PRTC) insider Robert Langer bought 93,944 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was purchased at an average cost of GBX 1 per share, with a total value of £939.44.

PureTech Health Stock Down 0.4%

Shares of LON PRTC traded down GBX 0.48 during mid-day trading on Friday, hitting GBX 119.12. 512,639 shares of the stock traded hands, compared to its average volume of 1,072,302. The company has a debt-to-equity ratio of 6.33, a quick ratio of 2.51 and a current ratio of 6.59. PureTech Health plc has a 52 week low of GBX 104.71 and a 52 week high of GBX 146.40. The company has a market cap of £289.96 million, a price-to-earnings ratio of -2.59 and a beta of 0.79. The stock has a fifty day moving average price of GBX 127.71 and a 200-day moving average price of GBX 126.71.

Analysts Set New Price Targets

Separately, Peel Hunt restated a “buy” rating and set a GBX 508 target price on shares of PureTech Health in a report on Monday, July 13th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of GBX 508.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.